Menu

Technology Technology

Walking
WITH PH patients

Pulmonary Hypertension（PH）
Pulmonary Hypertension（PH）
Pulmonary Hypertension (PH) is a clinical and pathophysiological syndrome of elevated pulmonary vascular resistance and pulmonary artery pressure caused by structural or functional changes in the pulmonary vasculature due to a variety of heterogenous diseases (etiology) and different pathogenesis, which can eventually progress to right heart failure or even death.

2.8

years
2.8 years The median survival rate for IPH after diagnosis

5

-

10

%
5-10% Adult CHD patients PAH prevalence rate

60

-

68

%
60-68% HFpEF patients PH prevalence rate

40

-

75

%
40-75% HFrEF patients PH prevalence rate
Pulmonary Artery Denervation
Pulmonary Artery Denervation
PADN is a potential global first-in-class, best-in-class innovative catheter interventional therapy for treating PH.
Explore

Multi-pole Pulmonary Artery RF Ablation Catheter

Multi-pole Pulmonary Artery RF Ablation Catheter

RF Ablation Generator

RF Ablation Generator

Disclaimer

The information displayed in this page is merely for introduction and demonstration of the two pieces of equipment, such equipment has not been approved by U.S. Food and Drug Administration.

Copyright © 2021 Pulnovo Medical

1

First-in-class catheter interventional therapy

16

Days received the Breakthrough Device Designation from FDA

4

+

International operations

15

+

SCI publications

20

+

International invited academic report

15

+

Practical invention patents

50

+

Over 50 Global Patent Portfolio

66

+

SCI impact factors
Global Recognition
Breakthrough Device Designation
Breakthrough Device Designation
Innovative green pathway
Innovative green pathway
Quality certification
Quality certification
Global Recognition
Over decades, 400+ cases
built up a solid evidence-based foundation for PADN
Animal study 1
《Eurointervention》
Firstly report the treatment effect of PADN in animals with increased haemodynamic parameters.
Animal study 2
《JACC Interv》
PADN induces permanent SN injury and subsequent improvements in hemodynamics and PA remodeling in animals with PAH through mechanisms that may be experimentally and clinically beneficial.
Animal study 3
《BMC Cardiovascular Disorders》
PADN improves hemodynamics and relieves RV dysfunction in dogs with PAH, which can be associated with the downregulating RAAS activity in local tissue.
Animal study 4
《Pulm Circ》
PADN is associated with significant improvements in hemodynamics and pulmonary artery remodeling for HF-PH.
FIM study
《JACC》
Report the safety and effectiveness of PADN on functional capacity and hemodynamics in patients with IPAH not responding optimally to medical therapy.
IPAH（Group ⅠPH)
《Circ Cardiovasc Interv》
Report the effect of PADN on functional capacity and hemodynamics in patients with IPAH not responding optimally to medical therapy.
Group Ⅰ,Ⅱ,Ⅳ PH
《Int J Cardiol Res》
PADN treatment is associated with significant improvement of 6MWD and less PAH-related event.
CpcPH-HF(Group Ⅱ)
《JACC Cardiovasc Interv》
Confirm that PADN is associated with significant improvements in hemodynamic and clinical outcomes in patients with CpcPH.
PAH(Group Ⅰ)
《JACC Cardiovasc Interv》
PADN results in significant improvements in survival at a medium of 4.8 years follow-up, especially in patients with PAH in FC 3-4.
PAH(Group Ⅰ)
PAH(Group Ⅰ)
PADN improved exercise capacity and clinical outcomes during 6-month follow-up for WHO Group I PAH patients.
PAH(Group Ⅰ)
PADN-CFDA（Submitting）
PADN improved exercise capacity and clinical outcomes during 6-month follow-up for WHO Group I PAH patients.

Privacy settings

We use cookies on your browser to customize content for your viewing and for analytics. If you click “Accept” or continue to browse our website, we assume you have agreed to our use of cookies. For details, please refer to our Cookies Policy.

Accept
Reject